This Study Tests How BI 655130 Works in Patients With Active Ulcerative Colitis. The Study Also Tests How Well BI 655130 is Tolerated and Whether it Helps the Patients
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Boehringer Ingelheim
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
18 - 75 years at screening
Diagnosis of UC \>= 3 months prior to screening.
Moderately to severely active UC as confirmed by Mayo Score ≥6
Receiving conventional, non-biologic therapy for UC.
Negative colon cancer screening
You may not be if
Prior use of any biological treatment in the past (e.g.integrin inhibitors, IL12/23 or IL23 inhibitors, any investigational biological drugs)
Extensive colonic resection
Evidence of infection with C. difficile or other intestinal pathogen \< 30 days prior to screening
Active or latent tuberculosis
Clareo Health | This Study Tests How BI 655130 Works in Patients With Active Ulcerative Colitis. The Study Also Tests How Well BI 655130 is Tolerated and Whether it Helps the Patients
